Highlights AVROBIO, Inc.

Equities

AVRO

US05455M1009

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.19 ^USD	-1.65%		-0.83%	-12.50%

Mar. 21	North American Morning Briefing : Investors -2-	DJ
Mar. 14	AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

North American Morning Briefing : Investors -2-	Mar. 21	DJ
AVROBIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
AVROBIO, Inc. entered into an agreement to acquire Tectonic Therapeutic, Inc.	Jan. 29	CI
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
AVROBIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
AVROBIO Says Exploring Strategic Alternatives to Boost Shareholder Value; Shares Jump	23-07-12	MT
Novartis Pharma AG and Novartis Pharmaceuticals Corporation completed the acquisition of Cystinosis Gene Therapy Program from AVROBIO, Inc..	23-06-08	CI
AVROBIO to Sell Cystinosis Gene Therapy Program to Novartis for $87.5 Million	23-05-22	MT
AVROBIO, Inc. Enters into an Asset Purchase Agreement with Novartis Pharma AG and Novartis Pharmaceuticals Corporation	23-05-22	CI
Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. for $87.5 million.	23-05-21	CI
AVROBIO, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
AVROBIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-23	AQ
Avrobio Reports 'Positive' Interim Data in Gaucher Disease Trial, Plans Phase 2/3 Study Next Year	22-12-07	MT
AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy	22-12-07	CI
Mission Bio Announces First-Time Deployment of One Single-Cell Transduction Assay Across Gene Therapy Company Avrobio's Lysosomal Disorder Pipeline	22-11-29	CI
AVROBIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease	22-10-27	CI
AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis	22-10-25	CI
AVROBIO Receives 'Innovation Passport' From UK Regulator to Accelerate Development of Gaucher Disease Gene Therapy; Shares Rise	22-10-18	MT
AVROBIO Receives 'Innovation Passport' From UK Regulator to Accelerate Development of Gaucher Disease Gene Therapy; Shares Rise	22-10-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AVROBIO, Inc.

Equities

AVRO

US05455M1009

Highlights

Filters